Compare Boston Scientific Corporation (BSX) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Oscar Health Inc — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Oscar Health Inc trades at $30.67 (market cap $9.37B). The key difference: Boston Scientific Corporation is far larger — about 7.1× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | OSCR | |
|---|---|---|
Market Cap | $66.37B | $9.37B |
Sector | Health | Health |
52-Week High | $108.14 | $32.18 |
52-Week Low | $42.63 | $10.85 |
Enterprise Value | $75.94B | $4.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
OSCR trades at $31.60, up 3.47% today, showing strong momentum near recent highs. The stock exhibits a bullish technical outlook with positive moving average signals and support at $31. Recent Q1 2026 earnings beat expectations with $2.07 EPS versus $1.21 expected, though the company remains unprofitable with a -0.3% net margin. Revenue growth is robust, projected to increase from $11.70B in 2025 to $13.30B in 2026, while operating cash flow strengthens significantly.
The outlook is mixed: strong revenue growth and cash flow improvements support upside potential, but persistent losses and high P/B ratio of 5.63 pose risks. Analyst consensus is cautious with a $22.50 price target below current levels, though technical momentum suggests near-term strength. Key risks include execution on profitability goals and competitive pressures in the health insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
